BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19003961)

  • 1. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer.
    Hesselink AT; Berkhof J; Heideman DA; Bulkmans NW; van Tellingen JE; Meijer CJ; Snijders PJ
    Int J Cancer; 2009 Jan; 124(2):381-6. PubMed ID: 19003961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
    Baasland I; Romundstad PR; Eide ML; Jonassen CM
    PLoS One; 2019; 14(1):e0210997. PubMed ID: 30673759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus viral load in predicting high-grade CIN in women with cervical smears showing only atypical squamous cells or low-grade squamous intraepithelial lesion.
    Santos AL; Derchain SF; Martins MR; Sarian LO; Martinez EZ; Syrjänen KJ
    Sao Paulo Med J; 2003 Nov; 121(6):238-43. PubMed ID: 14989139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology.
    Snijders PJ; Hogewoning CJ; Hesselink AT; Berkhof J; Voorhorst FJ; Bleeker MC; Meijer CJ
    Int J Cancer; 2006 Sep; 119(5):1102-7. PubMed ID: 16570279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia >or=2 in a liquid-based cytology setting?
    Boulet GA; Benoy IH; Depuydt CE; Horvath CA; Aerts M; Hens N; Vereecken AJ; Bogers JJ
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2992-9. PubMed ID: 19861526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of human papillomavirus (HPV) 16 and HPV18 viral loads for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a cohort of African women living with HIV.
    Segondy M; Ngou J; Kelly H; Omar T; Goumbri-Lompo O; Doutre S; Mayaud P; Didelot MN
    J Clin Virol; 2018; 99-100():79-83. PubMed ID: 29353074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
    Leeman A; Del Pino M; Marimon L; Torné A; Ordi J; Ter Harmsel B; Meijer CJLM; Jenkins D; Van Kemenade FJ; Quint WGV
    Int J Cancer; 2019 Jan; 144(1):160-168. PubMed ID: 30098013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.
    Del Mistro A; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Girlando S; Rizzolo R; Frayle H; Trevisan M; Sani C; Burroni E; Giorgi Rossi P; Cuzick J; Ronco G;
    Int J Cancer; 2018 Jul; 143(2):333-342. PubMed ID: 29453769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.
    Wang SS; Zuna RE; Wentzensen N; Dunn ST; Sherman ME; Gold MA; Schiffman M; Wacholder S; Allen RA; Block I; Downing K; Jeronimo J; Carreon JD; Safaeian M; Brown D; Walker JL
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):113-20. PubMed ID: 19124488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease.
    Gravitt PE; Kovacic MB; Herrero R; Schiffman M; Bratti C; Hildesheim A; Morales J; Alfaro M; Sherman ME; Wacholder S; Rodriguez AC; Burk RD
    Int J Cancer; 2007 Dec; 121(12):2787-93. PubMed ID: 17722112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Thomsen LT; Frederiksen K; Munk C; Junge J; Iftner T; Kjaer SK
    Int J Cancer; 2015 Jul; 137(1):193-203. PubMed ID: 25471319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
    Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
    J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma.
    Wentzensen N; Schiffman M; Dunn ST; Zuna RE; Walker J; Allen RA; Zhang R; Sherman ME; Wacholder S; Jeronimo J; Gold MA; Wang SS
    Int J Cancer; 2009 Feb; 124(4):964-9. PubMed ID: 19030188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.